Alzheimer's disease: Clinical implications of the apolipoprotein E genotype
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Article abstract-Inheritance of the apolipoprotein E (APOE = gene; apoE = protein) epsilon 4 gene is associated with a higher risk for development of Alzheimer's disease (AD) and for occurrence of this illness at a younger age. APOE gene dose and genotype interact with gender, ethnicity, and age to influence the probability of developing AD, as well as the rate of disease progression. The sensitivity and specificity of APOE genotyping, however, and the longer-term implications of the epsilon 4 allele as a susceptibility factor for AD, are not yet adequately understood to recommend the use of APOE genotyping in genetic counseling of asymptomatic family members of AD patients. Insufficient evidence also exists at this time to recommend APOE genotyping as an adjuvant for the differential diagnosis of dementia or as a possible predictor for response to drug therapy. These potential future clinical indications for apoE genotyping are under active investigation.
NEUROLOGY 1997;48(Suppl 6): S30-S34
- Copyright 1997 by Advanstar Communications Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
ApoE-4 and Age at Onset of Alzheimer's DiseaseThe NIMH Genetics InitiativeD. Blacker, J. L. Haines, L. Rodes et al.Neurology, January 01, 1997 -
Articles
Metrifonate treatment of ADInfluence of APOE genotypeM.R. Farlow, P.A. Cyrus, A. Nadel et al.Neurology, December 01, 1999 -
Articles
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairmentA. S. Fleisher, B. B. Sowell, C. Taylor et al.Neurology, February 07, 2007 -
Articles
Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's diseaseM. R. Farlow, D. K. Lahiri, J. Poirier et al.Neurology, March 01, 1998